China DNA Vaccine Market Share, Trends, Future Outlook, Analysis and Forecast 2023-2030

China DNA Vaccine market is anticipated to grow at a CAGR 42.8% during the forecast period. In China it is mandatory to inject the hepatitis B vaccine (HBV) and tuberculosis-TB (BCG) vaccine immediately to the child after birth as per Chinese law. China began its expanded program on Immunization (EPI) in 1992. It involves a mandatory 11-vaccine schedule which must be given to children from 0 to 6 years. The vaccination schedule is compulsory for Chinese citizens. The compulsory vaccines in the China are Hepatitis B (HBV), Japanese Encephalitis (JE) and Hepatitis A (HAV). Along with this, the recommended vaccines are Chickenpox, Rotavirus, and Rabies. China's Food and Drug Administration (CFDA) under the CNRA issues vaccine-manufacturing had provided license to 34 companies that meet the required international manufacturing practice requirements.

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/china-dna-vaccines-market

Researchers in China have developed an inexpensive, stable DNA vaccine that can protect against two of the four known serotypes of dengue virus. According to the World Health Organization, the dengue virus is one of the most rapidly spreading mosquito-borne pathogens. A tetravalent dengue vaccine that protects against all four serotypes of dengue virus (DV1-4) has been approved for use in some countries.

The market is segmented on the basis of type, application and technology. Based on type, the market is segmented into animal DNA vaccine and human DNA vaccine. Based on technology, the market is segmented into plasmid DNA vaccine and plasmid DNA delivery. Based on application, the market is segmented into oncology, infectious disease and others.

The key market players that are active in the market include Beijing Advaccine Biotechnology Co., Eli Lilly and Co., GE Healthcare, Glaxosmithkline PLC., Inovio Pharmaceuticals Inc., Merck & Co., Novartis AG, Pfizer Inc., Roche Diagnostics GMBH and Sanofi Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups and technological advancements to stay competitive in the market.

China DNA Vaccine Market Segmentation

By Type

Animal DNA Vaccine
Human DNA Vaccine

By Technology

Plasmid DNA Vaccine
Plasmid DNA Delivery

By Application

Oncology
Infectious Disease
Others

A full report of China DNA Vaccine Market available @ https://www.omrglobal.com/industry-reports/china-dna-vaccines-market

Company Profiles

Beijing Advaccine Biotechnology Co.
Eli Lilly and Co.
GE Healthcare
Glaxosmithkline PLC.
Merck & Co.
Novartis AG
Pfizer Inc.
Roche Diagnostics GMBH
Sanofi Inc.

Reasons to Buying From us -

We cover more than 15 major industries, further segmented into more than 90 sectors.
More than 120 countries are for analysis.
Over 100+ paid data sources mined for investigation.
Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:

Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

This release was published on openPR.